Timing and prognosis of brain metastasis development in breast cancer by subtype.

Authors

Narmeen S Rashid, Nayan Lamba, Ivy Ricca, Marciana Johnson, Paul J Catalano, Shyam K Tanguturi, Rifaquat Rahman, Daphne A Haas-Kogan, Patrick Y Wen, Sarah L Sammons, Nancy U Lin, Ayal A Aizer

Published in

JNCI cancer spectrum. Sep 23, 2026. Epub Sep 23, 2026.

Abstract

Limited data on the timing of brain metastases development and subsequent prognosis by breast cancer subtype exist. We retrospectively evaluated a cohort of 671 patients diagnosed with brain metastases secondary to breast cancer. Patients were categorized by subtype: human epidermal growth factor receptor 2-positive (HER2+), hormone receptor-positive/HER2-negative (HR+/HER2-), and triple negative (TN). We found significant heterogeneity in the timing of brain metastases development and subsequent prognosis by subtype. Patients with HR+/HER2- disease developed brain metastases later in the disease course compared to patients with HER2+ and TN disease. Median overall survival following brain metastases diagnosis was shortest in patients with TN disease; however, among all subtypes, overall survival decreased with an increasing number of systemic therapies prior to the diagnosis of brain metastases. Altogether, these findings may inform differential timing of brain-directed screening imaging in patients with breast cancer.

PMID:
42776601
Bibliographic data and abstract were imported from PubMed on 24 Sep 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.